you are here:
Success
Alert
Please select a Day.
Info
55.85
3.10 (5.88%)

As on 13 Apr, 2021 | 03:56

Trade
Day Range
52.00
56.90
L H
52 Week Range
18.05
66.20
L H
Volume
4,684,700
*
i

* BSE Market Depth (13 Apr 2021)

BUY SELL
QTY PRICE PRICE QTY
914 55.50 55.60 200
752 55.30 55.65 514
350 55.25 55.75 575
9 55.10 55.80 210
713 55.00 55.85 13575
21885 Total Total 123518
Bid / Ask
55.50 / 55.65
55.50
2.70 (5.11%)

As on 13 Apr, 2021 | 04:00

Day Range
52.20
56.85
L H
52 Week Range
18.05
66.10
L H
Volume
559,798
*
i

* BSE Market Depth (13 Apr 2021)

BUY SELL
QTY PRICE PRICE QTY
914 55.50 55.60 200
752 55.30 55.65 514
350 55.25 55.75 575
9 55.10 55.80 210
713 55.00 55.85 13575
21885 Total Total 123518
Bid / Ask
55.50 / 55.65
NSE

#KnowBeforeYouInvest

Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Note :Financial Information is based on consolidated numbers.
Financials
    Ownerships
      Industry Comparison
        Others
          Open53.40
          Previous Close52.75
          UC Limit63.30
          LC Limit42.20
          Volume4,684,700.00
          VWAP55.24
          Mkt Cap (Rs. Cr.)2,286
          20D Avg Volume2,279,654
          20D Avg Delivery1,065,425
          Beta0.680.63
          Face Value1.00
          TTM EPS4.93
          TTM PE11.33
          Sector PE40.28
          Book Value Per Share15.86
          P/B3.52
          Dividend Yield0.18
          P/C10.01

          Advance Chart

          Click here to expand

          *Refresh in 20 seconds.

          MC Insights

          Strong Performer: Stock with good financial performance alongside good to expensive valuation, but lacks price momentum as suggested by technical indicators

          Price
          • Mid Range Momentum - Stock is Mid Range compared to Short, Medium and Long Term Moving Averages
          • 209.42% away from 52 week low
          • 15.63% away from 52 week high
          • Underperformer - Marksans Pharma down by -5.5% v/s NIFTY 50 down by -3.5% in last 1 month
          Financials
          Piotroski Score
          i
          Piotroski F-Score determines the financial strength of the company and ranges between 0 to 9. Higher the score, better the financials of the company.
          9

          indicates Strong Financials

          3 year CAGR growth
          Revenue 13.6%
          NetProfit 120.0%
          OperatingProfit 62.6%
          Industry Comparison
          • TTM PE Ratio - Below industry Median
          • Market Cap - Above industry Median
          • Price to Book Ratio - Above industry Median
          • TTM PEG Ratio - Below industry Median
          Shareholding Pattern
          • Promoters holding remains unchanged at 48.25% in Dec 2020 qtr
          • Mutual Funds have increased holdings from 0.0% to 0.01% in Dec 2020 qtr.
          • Number of MF schemes remains unchanged at 1 in Dec 2020 qtr
          • FII/FPI have increased holdings from 3.73% to 3.79% in Dec 2020 qtr.
          • Number of FII/FPI investors increased from 54 to 62 in Dec 2020 qtr.
          • Institutional Investors have increased holdings from 4.98% to 5.35% in Dec 2020 qtr.

          MC Technicals

          TECHNICAL RATING
          i
          This represents current trend.
          Click here for disclaimer.
          Moving Averages Bearish
          Technical Indicators Bearish
          Moving Averages Crossovers Bearish

          Pivot levels

            R1 R2 R3 PP S1 S2 S3
          Classic - - - - - - - - - - - - - -
          Fibonacci - - - - - - - - - - - - - -
          Camarilla - - - - - - - - - - - - - -

          Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

          Pivot levels

          R1 - - Pivot
          - -
          S1 - -
          R2 - - S2 - -
          R3 - - S3 - -

          Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.

          Moving Averages
          Days
          5 - -
          10 - -
          20 - -
          50 - -
          100 - -
          200 - -
          TECHNICAL RATING
          i
          This represents current trend.
          Click here for disclaimer.
          Moving Averages Bearish
          Technical Indicators Bearish
          Moving Averages Crossovers Bearish

          Pivot levels

          Type R1 R2 R3 PP S1 S2 S3
          Classic - - - - - - - - - - - - - -
          Fibonacci - - - - - - - - - - - - - -
          Camarilla - - - - - - - - - - - - - -

          Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.

          Pivot levels

          R1 - - Pivot
          - -
          S1 - -
          R2 - - S2 - -
          R3 - - S3 - -

          Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.

          Moving Averages
          Days
          TECHNICAL RATING
          i
          This represents current trend.
          Click here for disclaimer.
          Moving Averages Bearish
          Technical Indicators Bearish
          Moving Averages Crossovers Bearish

          Pivot levels

          Type R1 R2 R3 PP S1 S2 S3
          Classic - - - - - - - - - - - - - -
          Fibonacci - - - - - - - - - - - - - -
          Camarilla - - - - - - - - - - - - - -

          Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

          Pivot levels

          R1 - - Pivot
          - -
          S1 - -
          R2 - - S2 - -
          R3 - - S3 - -

          Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.

          Moving Averages
          Days

          Price and Volume

          Price Performance
          1 Week
          --%
          1 Month
          --%
          3 Months
          --%
          YTD
          --%
          1 Year
          --%
          3 Years
          --%
          Volume Analysis

          Forum

          Community Sentiments

          • 100% BUY
          • 0% SELL
          • 0% HOLD
          100%
          of moneycontrol users recommend buying Marksans Pharma

          What's your call on Marksans Pharma today?

          Read 10 investor views

          BUY SELL HOLD

          Broker Research

          No Data For Broker Research.

          Deals

          18 Nov, 2008

          ANJALI CHAWLA

          Qty 1995747 Price 6.03 % Traded 0.49
          18 Nov, 2008

          KABUL CHAWLA

          Qty 1995747 Price 6.03 % Traded 0.49

          *Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.

          21 Sep, 2018

          THE VANGUARD GROUP INC A/C VANGUARD EMERG. MKTS STOCK INDE

          Qty 2343202 Price 33.23 % Traded 0.57
          06 Aug, 2018

          PARTH INFIN BROKERS PVT LTD

          Qty 2245387 Price 33.05 % Traded 0.55
          06 Aug, 2018

          PARTH INFIN BROKERS PVT LTD

          Qty 2270387 Price 33.11 % Traded 0.55
          10 Apr, 2017

          SHAASTRA SECURITIES TRADING PRIVATE LIMITED

          Qty 2957519 Price 55.29 % Traded 0.72
          10 Apr, 2017

          SHAASTRA SECURITIES TRADING PRIVATE LIMITED

          Qty 2957519 Price 55.32 % Traded 0.72
          20 Sep, 2016

          PARTH INFIN BROKERS PVT LTD

          Qty 3830711 Price 49.31 % Traded 0.94
          20 Sep, 2016

          PARTH INFIN BROKERS PVT LTD

          Qty 3826611 Price 49.3 % Traded 0.93
          18 Mar, 2016

          VANGUARD INTERNATIONAL EXPLORER FUND

          Qty 2366133 Price 50.09 % Traded 0.58

          *A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.

          Insider Transaction Summary

          Mar, 02, 2020

          Mr. Sebastian Pereira

          Employee
          Qty 5000 Price 85.08 % Traded 0.00 Post Tnx Hold. 0%
          Mar, 02, 2020

          Mr. Sebastian Pereira

          Employee
          Qty 2800 Price 95.22 % Traded 0.00 Post Tnx Hold. 0%
          Mar, 02, 2020

          Mr. Sebastian Pereira

          Employee
          Qty 100 Price 104.63 % Traded 0.00 Post Tnx Hold. 0%
          Mar, 02, 2020

          Mr. Sebastian Pereira

          Employee
          Qty 5100 Price 108.6 % Traded 0.00 Post Tnx Hold. 0%
          Sep, 22, 2016

          Harsh Trehon

          Employee
          Qty 69900 Price 49.74 % Traded 0.02 Post Tnx Hold. 0%

          *Disclosures under SEBI Prohibition of Insider Trading Regulations, 2015

          No Data For Substantial Acquisition of Shares & Takeovers.

          *Disclosures under SEBI SAST (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

          Financials

          • Revenue
          • Net Profit
          • EPS
          • Revenue
          • Net Profit
          • EPS

          Shareholding

          PEERS

          Company Name Price % Chg MCap(Cr) TTM PE P/B ROE 1 Yr Perform Net Profit Net Sales Debt to Equity
          Marksans Pharma 55.85 5.88 2286.02 11.33 3.52 18.98 148.78 120 1,134 0.03
          Sun Pharma 627.35 1.29 150522.28 58.74 3.06 8.31 35.69 4,186 32,837 0.17
          Divis Labs 3718.45 -1.62 98713.16 52.77 13.50 18.83 58.83 1,376 5,394 0.00
          Dr Reddys Labs 4777.30 -4.40 79447.09 36.52 5.09 12.98 27.51 1,969 17,517 0.11
          Cipla 885.20 -1.91 71388.13 31.91 4.46 9.81 49.31 1,546 17,131 0.18

          About the Company

          Marksans Pharma Limited together with its subsidiaries operates as an integrated international pharmaceutical company. The Companys business is distribution of pharmaceutical products. It is actively engaged in research and development (R&D) and offering contract research and manufacturing services (CRAMS) to global pharmaceutical companies. The R&D capability of the Company includes dossier development service, formulation development and specified drug delivery system. The Companys domestic formulation business is the specialty division, which mainly focuses on oncology and critical care therapy. The brands of this division are MARKPARIN and EPIGROF. EPIGROF is also being supplied to hospitals and other burns and trauma care institutes. Cerebella division is the specialty division marketing drugs meant for lifestyle diseases, neuro and psychiatric therapy. The brands of this division are BAZZY, CITOFAST, GABELLA, GABELLA M, XENOTRIL, which are the main contributors of sales.
          {"success":1,"data":{"address":{"address1":"11th Floor, Grandeur,","address2":"Veera Desai Extension Road,,Oshiwara,","city":"Mumbai","state":"Maharashtra","pincode":"400053","telephone1":"022-40012000","telephone2":"","fax1":"022-40012011","fax2":"","email":"companysecretary@marksanspharma.com","web":"http:\/\/www.marksanspharma.com"},"management":[{"name":"Mark Saldanha","designation":"Chairman & Managing Director"},{"name":"Sandra Saldanha","designation":"Whole Time Director"},{"name":"Varddhman V Jain","designation":"Whole Time Director"},{"name":"Seetharama R Buddharaju","designation":"Independent Director"},{"name":"Digant Mahesh Parikh","designation":"Independent Director"}],"registrars":{"name":"Bigshare Services Pvt. Ltd.","address1":"1st Floor, Bharat Tin Works Building,","address2":"Opp. Vasant Oasis, Makwana Road, Marol,","address3":"Andheri (East),","address4":"","telephone":"022-62638200","fax":"022-62638299","email":"investor@bigshareonline.com","internet":"http:\/\/www.bigshareonline.com","city":"Mumbai","state":"Maharashtra","pincode":"400059"},"listing":[{"name":"BSE 100","value":"No"},{"name":"BSE 200","value":"No"},{"name":"SENSEX","value":"No"},{"name":"CNX MIDCAP 200","value":"No"},{"name":"NIFTY 50","value":"No"},{"name":"BSE 500","value":"No"}],"details":{"bseId":"524404","nseId":"MARKSANS","series":"EQ","isinid":"INE750C01026"}}}
          • Registered Office

          • Registrars

          • Management

            • Mark Saldanha

              Chairman & Managing Director

            • Sandra Saldanha

              Whole Time Director

            • Varddhman V Jain

              Whole Time Director

            • Seetharama R Buddharaju

              Independent Director

            • Digant Mahesh Parikh

              Independent Director

          • Included In

            • BSE 100

              No

            • BSE 200

              No

            • SENSEX

              No

            • CNX MIDCAP 200

              No

            • NIFTY 50

              No

            • BSE 500

              No

          • Details

            • BSE:

              524404

            • NSE:

              MARKSANS

            • Series

              EQ

            • ISIN

              INE750C01026

          Your feedback matters! Tell us what we got right and what we didn’t? Click here>